{"id":"NCT01240863","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time","officialTitle":"A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2010-11-15","resultsPosted":"2017-06-05","lastUpdate":"2017-06-05"},"enrollment":391,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain"],"interventions":[{"type":"DRUG","name":"Hydrocodone ER","otherNames":["CEP-33237","Hydrocodone bitartrate extended-release"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Hydrocodone ER","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate efficacy of hydrocodone extended-release (ER) tablets compared with placebo in alleviating moderate to severe pain in patients with osteoarthritis or low back pain as assessed by the weekly Average Pain Intensity (API) at week 12.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in Weekly Average Pain Intensity (wAPI)","timeFrame":"Baseline (end of Open-Label Titration Period), Week 12 of Double-blind Treatment Period","effectByArm":[{"arm":"Placebo (Double-blind Treatment Period)","deltaMin":0.14,"sd":0.169},{"arm":"Hydrocodone ER (Double-blind Treatment Period)","deltaMin":-0.22,"sd":0.176}],"pValues":[{"comp":"OG000 vs OG001","p":"0.134"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":18},"locations":{"siteCount":73,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":389},"commonTop":["Nausea","Constipation","Headache","Somnolence","Vomiting"]}}